CXCR1 and COVID-19: Among all severe COVID-19 patients, 152 (61%) required vasopressor support, 192 (77%) received HCQ, 87 (35%) received azithromycin, 26 (10%) received Tocilizumab alone without CC, 69 (27%) received CC alone without Tocilizumab, 92 (37%) received combination therapy with both Tocilizumab and CC, and 65 (26%) received convalescent plasma.